3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Specimen Handling
8
pembrolizumab
7
enfortumab vedotin
7
Magnetic Resonance Spectroscopy
6
avelumab
4
Nivolumab
4
Gemcitabine
3
cabozantinib
2
Ipilimumab
2
Immunoglobulin G
2
Disulfides
2
Cisplatin
2
Carboplatin
2
CTLA-4 Antigen
2
Biopsy
2
vinflunine
1
tremelimumab
1
tocilizumab
1
tamibarotene
1
relatlimab
1
eribulin
1
erdafitinib
1
durvalumab
1
copanlisib
1
atezolizumab
1
Watchful Waiting
1
Standard of Care
1
Propranolol
1
Practice Guidelines as Topic
1
Plasmapheresis
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ureteral Neoplasms
×
tamibarotene
×
1 year
×
Clear all
NCT06983210
2025-08-14
GRAPE
Nagoya University
Phase 2
Recruiting
43 enrolled